throbber
3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 1
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
` _________________
`
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
` _________________
`
`
` ARGENTUM PHARMACEUTICALS LLC
` Petitioner
` v.
` CIPLA LTD.
` Patent Owner
` _________________
` Case IPR2017-0087
` Patent 8,168,620
` _________________
` DEPOSITION OF ROBERT P. SCHLEIMER, Ph.D.
` March 30, 2018
` Chicago, Illinois
`______________________________________________
` DIGITAL EVIDENCE GROUP
` 1730 M Street, NW, Suite 812
` Washington, D.C. 20036
` (202) 232-0646
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`1
`
`CIP2179
`Argentum Pharmaceuticals v. Cipla Ltd.
`IPR2017-00807
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 2
` The deposition of ROBERT P. SCHLEIMER, Ph.D.,
`called by the Patent Owner for examination, taken
`before Cynthia J. Conforti, CSR, RPR, CRR, at Foley
`& Lardner LLP, 321 North Clark Street, Suite 2800,
`Chicago, Illinois, commencing at the hour of
`9:08 a.m. on the 30th day of March, A.D., 2018.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7 8 9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`2
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 3
`
`A P P E A R A N C E S:
`ON BEHALF OF THE PETITIONER:
` FOLEY & LARDNER LLP
` 321 North Clark Street
` Suite 2800
` Chicago, Illinois 60654-5313
` 312.832.4500
` BY: MICHAEL R. HOUSTON, ESQ.
` mhouston@foley.com
`
`ON BEHALF OF THE PATENT HOLDER:
` STERNE, KESSLER, GOLDSTEIN & FOX PLLC
` 1100 New York Avenue, NW
` Washington, DC 20005
` 202.772.8979
` BY: JOSHUA I. MILLER, ESQ.
` jmiller@sternekessler.com
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`3
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 4
`
` INDEX
`TESTIMONY OF ROBERT P. SCHLEIMER, Ph.D. PAGE
`Examination by Mr. Miller 6
`Examination by Mr. Houston 110
`
` DEPOSITION EXHIBITS
`NUMBER DESCRIPTION PAGE
`Exhibit 1001 U.S. Patent 8,168,620 B2 29
` (15 pages)
`Exhibit 1003 Declaration of Schleimer 102
` (60 pages)
`Exhibit 1011 European Patent Application 33
` EP 0 780 127 A1
` (9 pages)
` Exhibit 1144 Second
` Declaration of Schleimer
` (71 pages)
`Exhibit 1012 International Application 33
` WO 09/48839
` (13 pages)
`Exhibit 1031 Juniper article 75
` (9 pages)
`
`1
`
`2
`
`3
`
`4
`
`5 6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`4
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 5
`
` DEPOSITION EXHIBITS (Continued)
`NUMBER DESCRIPTION PAGE
`Exhibit 1035 Drouin article 21
` (10 pages)
`Exhibit 1038 Brooks article 59
` (7 pages)
`Exhibit 1041 Galant article 12
`Exhibit 1045 Ratner article 94
` (8 pages)
`Exhibit 1055 Dr. Accetta Patient Record 8
` (1 page)
`Exhibit 1148 Han article 107
` (6 pages)
`Exhibit 1160 "Clinical Therapeutics" 107
` (12 pages)
`CIP2041 Howarth article 62
` PTX0337-00001 - 6
`CIP2042 Nielsen article 62
` PTX0338-00001 - 17
`CIP2147 Second Declaration of 46
` Carr
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`5
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 6
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` (Witness sworn.)
` ROBERT P. SCHLEIMER, Ph.D.,
`having been duly sworn, was examined and testified
`as follows:
` DIRECT EXAMINATION
`BY MR. MILLER:
` Q. All right, Dr. Schleimer. How are you
`doing this morning?
` A. I am doing all right. How are you?
` Q. All right. Great. We have had a couple
`depositions in related matters, related to the '620
`patent. You testified previously in Apotex
`litigation between Meta and Cipla against Apotex,
`correct?
` A. Against Apotex?
` Q. No, I'm sorry. The case was Meta and
`Cipla versus Apotex. You testified --
` A. Yes, I testified in that case.
` Q. -- on Apotex's behalf.
` And now we're here. You're testifying on
`behalf of Argentum Pharmaceuticals?
` A. That is correct.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`6
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 7
` Q. And the '620 patent was involved in both
`litigations?
` A. Yes.
` Q. Okay. I want to start with Exhibit 1144,
`which is your second declaration in this IPR.
` A. Okay.
` Q. One of the things that you talk about here
`is the early and late phase, and your view is that
`those are relevant to clinical therapy, correct?
` A. Yeah, they're often relevant to clinical
`therapy. They're more relevant as a way to
`understand allergic reactions.
` Q. Okay. And so this is -- the phases are
`really the mechanism of the disease itself, part of
`the mechanism of the disease itself, and not really
`the symptom; is that right?
` A. Well, the phases are indicators of the
`underlying mechanisms, but the mechanisms are what
`drive the symptoms, so you can't unlink them.
` Q. Okay. Now, I'd like to flip to
`paragraph 54 in your declaration if we could. It's
`page 37.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`7
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 8
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` A. Okay.
` Q. You talk about Dr. Accetta's records here,
`correct?
` A. Yes.
` Q. Now, just to be clear, Dr. Accetta was a
`physician who testified in the Apotex litigation?
` A. That's right.
` Q. And he's a physician, correct?
` A. Yes.
` Q. You are not.
` A. That's correct.
` Q. So you do not treat patients?
` A. Correct.
` Q. Okay. Let me hand you -- this is
`Exhibit 1055.
` MR. HOUSTON: And just to be clear, I think the
`original was in color, wasn't it? Or am I
`remembering that wrong?
` MR. MILLER: Yes, it is in color.
` MR. HOUSTON: I don't know that it matters,
`but...
` MR. MILLER: Fair enough.
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`8
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 9
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` MR. HOUSTON: Okay.
`BY MR. MILLER:
` Q. And this was also used in Dr. Carr's
`deposition, which is why you see the exhibit at the
`top there. This is one of the exhibits that
`Dr. Accetta testified about in trial, correct,
`Dr. Schleimer?
` A. I believe so.
` Q. And you rely on this in paragraph 54.
`This is the prescription that you're talking about?
` A. I believe that's correct.
` Q. Okay. Now, to be clear, Dr. Carr is a
`clinician. He treats patients, right?
` A. Yes.
` Q. Dr. Accetta treats patients?
` A. Yes.
` Q. You do not.
` A. Correct.
` Q. So when you say that your interpretation
`of this -- and let's back up a second.
` So you can't actually see the complete
`record that's buried under this callout, correct?
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`9
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 10
`
`If you look, there's --
` A. That's correct. It covers the writing
`underneath.
` Q. Okay. Now, the underlying document there,
`the document you're referring to in 54, Dr. Carr and
`Dr. Accetta actually write these documents
`themselves, don't they?
` A. Yes --
` Q. And you don't.
` A. -- usually.
` That's correct. We've established I am not
`a physician.
` Q. Okay. And I just wanted to clarify that
`you don't actually ever write these things?
` A. Correct.
` Q. So you wouldn't know what a doctor is
`thinking when he puts down, for example, under the
`general:
` Patient's physical exam is normal.
` A. Well, I can certainly have -- I can read
`the English language. I'm very familiar with
`medicine and the practice of medicine, and in my
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`10
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 11
`recollection Dr. Carr had made a statement in his
`declaration or maybe it was his deposition, I don't
`remember, that he wouldn't treat a normal patient
`with these drugs, and in this case Dr. Accetta said
`the patient's physical examination is normal.
` And my take of Dr. Carr's statements was
`that he was suggesting that the patient being normal
`doesn't have allergic disease, so that was what the
`issue was.
` MR. MILLER: Okay. And just for the record,
`Mr. Marghese just joined us.
` MR. MARGHESE: Good morning, Dr. Schleimer.
`BY MR. MILLER:
` Q. Okay. So we can put that aside for a
`moment.
` I've handed you -- I'm going to hand you
`in just a moment an article by Stanley Galant, or is
`it Galant? I always mix this up.
` A. Galant is the way I pronounce it, but it
`may be wrong.
` Q. You're familiar with this?
` A. I have seen it, yes.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`11
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 12
` Q. Okay. Flip in your declaration quickly to
`paragraph 7, returning to the early-late phase
`concept that we talked about a minute ago.
` A. Okay.
` Q. You see from the header this is the
`section of your declaration that discusses the early
`and late phase and how they're clinically relevant
`prior to 2002, correct?
` A. Yes.
` Q. All right. So looking at paragraph 7
`here, you dispute Dr. Carr's view that the early and
`late phase are not relevant to clinical treatment of
`patients. Is that essentially an accurate summary
`of what you wrote there?
` A. I believe that they are relevant to not
`only the understanding of allergic disease but also
`to the treatment of allergic disease.
` Q. Okay. Now, the Galant reference I just
`handed you, Exhibit 1041, you see that, and that's
`cited in paragraph 7 of your declaration?
` A. Yes.
` Q. It's page 455. Can you flip to page 455
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`12
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 13
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`for me? Take a moment.
` I assume that the reference that you're
`citing here, the portion of this article that you're
`citing in paragraph 7 is Section 3, the pathogenesis
`section?
` A. Well, that section certainly mentions the
`early and the late phase and the mediators and
`cellular responses that are involved in those two
`distinguishable phases, yes.
` Q. Okay. Now, I just want to explore this
`document a little bit because you also talked a good
`deal about the context of an article in your
`declaration. If you look at Section 2 immediately
`preceding the section you just reviewed?
` A. Reviewed. You mean Section 4?
` Q. No. Go back to Section 2, the one
`immediately preceding, Evaluation and Diagnosis, so
`evaluation and diagnosis is what a physician does
`when he has a patient, correct?
` A. Yes.
` Q. All right. Go ahead and take a look at
`that and tell me if you see the word "phase"
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`13
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 14
`
`anywhere.
` A. I take it by the fact you're asking me that
`I won't find it. I skimmed it, I don't see it, but
`that doesn't mean that the symptoms or the
`manifestations of allergic disease are not mediated
`by the pathogenic events that are discussed fairly
`well in paragraph 3 or Section 3.
` Q. But the concept in section 2 is
`essentially that when you're evaluating a patient
`with allergic rhinitis you look at their history.
`You look at their symptoms. Doesn't say anything
`about phase. Is that accurate?
` A. I think it's context dependent. If a
`physician has a patient in front of them that
`reports that when they go visit a friend who has a
`cat and they start sneezing wildly, and then they go
`home and in the middle of the night they can't sleep
`because they're wheezing or they have complete
`blockage, the physician in that case will say, "Oh,
`well, that's classic early phase and late phase of
`an allergic response," so it's very case dependent.
`So I wouldn't agree with what you said. I think
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`14
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 15
`that all well-trained allergists understand about
`phases and how they contribute to disease.
` Q. Okay. And that's a very helpful answer in
`terms of understanding, but I just want to be clear
`that the evaluation and diagnosis section does not
`say anything about phase.
` A. This paragraph that you directed me to does
`not say anything about phase, but that does not
`embrace the totality of evaluation and diagnosis of
`allergic disease.
` Q. Okay. Now, you mentioned Section 4.
`Title is "Treating AR in the Child," correct?
` A. I see that, yes.
` Q. All right. And that's the one after the
`section that you talked about, pathogenesis, in your
`paragraph 7?
` A. Yes.
` Q. I'll represent to you, because this is far
`too long to ask you to read, but the only place that
`the word "phase" appears in the treatment section is
`on page 456 of the article that's stamped 04. You
`see "Histamine H1 Receptor Antagonists"?
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`15
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 16
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` A. I see that section, yes.
` Q. So you'll see -- the easiest way to find
`it is "in vivo," there's an "in vivo" in italics.
`The sentence after that, can you read that for the
`record?
` A. The sentence after?
` Q. "In vivo, the second generation
`antihistamine"?
` A. I'm sorry, I still don't know where
`you're --
` Q. All right. Towards the bottom under the
`header 4.1.
` A. Okay.
` Q. Towards the bottom of the left column
`there's a sentence that begins: The
`second-generation antihistamine?
` A. "The second-generation antihistamine
`cetirizine," that one --
` Q. Yes.
` A. -- that sentence?
` Q. Yes, please.
` A. -- "inhibits LTC4 and D4 production in
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`16
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 17
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`nasal secretions and inhibits recruitment of
`eosinophils in the cutaneous late-phase model."
` Q. So I'll represent to you, because I've
`read this and searched a couple times, that's the
`only place that "phase" appears in the treatment.
` And I want to be clear about what that is
`talking about. Cutaneous models are actually skin
`tests, correct?
` A. Yes.
` Q. So that's not allergic rhinitis.
` A. No, but it's a way that an allergist
`determines whether a patient is allergic to what's
`called an arrow allergen, which is an inhaled
`allergen. If you have allergic responses in your
`skin, you will also have the same allergic responses
`in your nose, so for convenience, since it's very
`difficult to test the nose, allergists will test the
`skin. If you respond to birch pollen in your skin,
`then it informs the allergist that you also will
`respond to birch pollen in your nose.
` Q. Okay. But, again, if you'll accept my
`representation that the reference to "late phase" in
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`17
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 18
`that sentence you just read is the only one, I want
`to talk about a couple of the other --
` A. Well, but hang on. You said it's the only
`one in diagnosis of disease.
` Q. This is treatment.
` A. In treatment. You said "diagnosis and
`treatment."
` And the fact is that this is not some huge
`document that describes the totality of diagnosis
`and treatment. This is a review that a couple of
`guys wrote in a second- or third-string journal and
`gave their impression of an overview of a few
`topics. So, you know, I think if you look
`throughout the documents that are under discussion
`in this case, of which there are dozens, a very
`large number of them mention the phases, and the
`phase is irrelevant not only in pathogenesis, but
`irrelevant in symptoms, manifestation of disease,
`and sometimes in diagnosis of disease.
` Q. Okay. But to be clear, this -- you've
`actually cited this article --
` A. Yes.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`18
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 19
`
` Q. -- that's in paragraph 7, correct?
` A. Yes. The reason that I cited it is because
`it has a nice little description of the differences
`between the early phase and the late phase, and
`those differences bear direct relevance to the
`actions of drugs with the antihistamines being very
`effective against the early phase, which is a
`antihistamine-driven response to great extent, and
`the steroids being very effective against the late
`phase which is mediated by infiltration of
`inflammatory cells and the subsequent release of
`mediators by those cells. So that goes straight to
`the complementarity argument. It was very well
`known before the priority date by people in the
`field that the steroids targeted that cellular
`inflammation and the release of mediators
`secondarily in the late phase, and the
`antihistamines were very good at working quickly
`against the immediate response to antigen, which is
`largely mass cells releasing histamine; so the skin
`tests that you were talking about can be blocked
`nearly completely with antihistamines. In fact, if
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`19
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 20
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`a patient has taken oral antihistamines, an
`allergist won't even bother to skin test them
`because they will have no skin test response.
` So on the other hand, you can take huge
`doses of oral steroids, and it will not inhibit that
`immediate skin test response one iota. So that's a
`perfect example of what an allergist would know,
`which is that antihistamines target the immediate
`response, including the skin test, and steroids
`inhibit the late-phase response.
` Q. Now, going back to the sentence you read
`in 4.1, that says that an antihistamine works in the
`late-phase model; is that right?
` A. Yes. So as I've mentioned in several of
`the documents during this case, there was the
`realization that some antihistamines, not all
`antihistamines, have some anti-inflammatory effects,
`and that includes the things mentioned here and many
`other things that are actually summarized in several
`of the documents. For example, Berger also
`summarizes them. It's less well established whether
`the various antihistamines have those profound
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`20
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 21
`anti-inflammatory effects in vivo, but there is
`reason to believe that topical antihistamines, which
`includes azelastine and levocabastine, can exert
`some of those particularly well because they can be
`given topically to create high concentrations in the
`nose. Much of the literature that serves as the
`basis for this concept is in vitro, and in vitro a
`scientist has no limitation on the amount of drug
`they can put in, so very large amounts of drug can
`inhibit responses that are known to be important.
`But if those concentrations can't be reached in vivo
`with either oral or local administration of a drug,
`then it's only theoretical but not actual useful
`information.
` Q. Okay. Thank you, Doctor.
` Next we are going to look at -- if you
`flip back to paragraph 7, the next article that you
`cite in that string there is Exhibit 1041, which I'm
`going to hand you in just a moment.
` A. Oh, we're still with 1041?
` Q. Oh, sorry. Did I say 1041? I meant 1035.
` MR. MILLER: Mike. Ma'am.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`21
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 22
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`BY MR. MILLER:
` Q. All right. So 1035 here, this is a Drouin
`article which you're familiar with, I assume?
` A. Yes.
` Q. And that's the article cited in
`paragraph 7, second paragraph cited in paragraph 7;
`is that right?
` A. Okay.
` Q. You cite page 341, which is the second
`page, first after the cover?
` A. Uh-huh, yes.
` Q. Now, looking at this, I'm assuming, take a
`moment to read through, but you're probably
`referring in paragraph 7 to this third paragraph,
`the nasal response to allergen?
` A. Yes. The third paragraph would be part of
`that, I believe.
` Q. Okay. Read the next paragraph. Begins
`"topical steroids" quickly for me, please.
` A. Topical steroids.
` Q. Oh, no, you don't have to read it on the
`record, sir. Just take a look at it. I'm going to
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`22
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 23
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`ask you a couple questions.
` A. Sorry.
` Q. That's okay.
` A. Okay.
` Q. So here, again, we see kind of a dichotomy
`where you talk about the phases, they are there, but
`the next paragraph is actually talking about how to
`treat patients, what symptoms they have and what
`drugs to use to treat them.
` A. Yes.
` Q. So, again, when actually talking about
`treating patients, the word "phase" did not appear
`in the paragraph, correct?
` A. It did not appear in the paragraph, but we
`know a lot about the mediators that cause the
`various symptoms.
` For instance, we know very well that
`histamine, when released quickly, causes sneezing
`and that -- for example.
` So the underlying allergic response is
`complex. It involves not only the immediate
`response of mass cells, but then many different cell
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`23
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 24
`types come into the tissue, and they each start
`singing in a chorus, and that results in symptoms.
`And what Drouin is saying is that the congestion
`seems to be related to that later response, the
`late-phase response with all of those cells coming
`in, and steroids are very good at inhibiting that.
`The early response is like itching and sneezing
`which happen right away. The steroids don't inhibit
`those well, at least not quickly, and we know those
`to be mediated by histamine because we can
`administer a histamine to the nose of even a normal
`healthy person, and they'll start sneezing
`immediately, and we know that the antihistamines
`will block that very well.
` Q. Okay. If you'll flip to page 344. It's
`been stamped at page 5.
` A. Okay.
` Q. The table of the actual data that they
`were looking at.
` A. Yes.
` Q. Does the word "phase" appear anywhere in
`there?
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`24
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 25
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` A. It does not.
` Q. Again, they're looking at symptoms,
`correct?
` A. It might be helpful if I explain that the
`phases originally come out of experimental allergic
`reaction studies, so these are studies where someone
`with allergy, again, let's say to birch pollen, is
`brought into the clinic, and let's say outside of
`the birch pollen season, so they have no symptoms.
`And then birch pollen is put into their nose to give
`them an allergic response, very similar to what
`happens if they go outside when the birch trees are
`pollenating during the season. And what happens in
`that setting, and this has been known for almost a
`century, and everyone knows it who studies allergy,
`what happens is they have an immediate response or
`an early-phase response, and that involves all the
`things that we've discussed like itching and
`sneezing, some runny nose, and then after 4 to
`8 hours, 10 hours and maybe lasting for a day or
`two, there's a late response, which may include a
`second wave of sneezing but also congestion and
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`25
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 26
`other things. So that's how -- and then further
`studies have shown what I said before and what
`Galant says which is that inflammatory cells come
`into the tissue and drive that late phase.
` So in the clinical setting, in clinical
`trials, it depends on the nature of the trial. If
`it's a trial that's using normal seasonal exposure
`to allergens, and the seasonal exposure lasts for
`weeks or months, as is true with these, then the
`phases -- the phases are not coming to play in that
`situation.
` If, on the other hand, there are many
`studies, none in this case where antigen challenge
`is administered and you can study the action of
`drugs, in those cases the phases are very much in
`play, and in our first meeting in this case we
`talked a little bit about antigen challenges but not
`in the second declaration.
` So this is a study where they looked at
`symptoms over a week or so, collecting data
`critically on Day 3 and Day 7, which is the early,
`early part of the treatment response, where I
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`26
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 27
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`maintain that these two drugs were known to be
`highly complementary, but it's not an
`antigen-challenge study, so there's no need to
`mention the phases. That doesn't mean that the
`components of the phases are not driving these
`symptoms. Allergists will know that they are.
` Q. You can put that off to the side, Doctor.
` A. Sure. I'm sure we'll get back to it.
` Q. At some point we probably will.
` I've asked you this before, but just for
`the sake of this deposition, you're not a
`formulator?
` A. That is not my job, correct. I am not a
`formulator, professional formulator. I've done it
`on occasion, but that's not my job.
` Q. You say you've done it on occasion. Can
`you give me a couple examples?
` A. Well, we did some studies with a drug
`decades ago that we administered to people, a simple
`formulation.
` Q. What's the simple formulation?
` A. It was just saline that was adjusted for
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`27
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 28
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`pH.
` Q. So you're not involved in the selection of
`excipients or, for example, particle size or
`anything like that?
` A. That's correct. I may not -- I have a
`minimal working knowledge of it. I understand many
`of the concepts and certainly in the court case
`heard Maureen Donovan, who is world class, discuss
`the issues not only in this case but generally in
`formulation for intranasal drugs.
` Q. If you'll flip to paragraph 5. It's the
`second page of declaration, second declaration,
`there's Footnote 1 down there. You see that?
` A. Yes, I see that.
` Q. Now, here you're responding to Dr. Carr
`mentioned in his declaration that you had not said
`anything about Claims 4 and 42 through 44.
` A. Yes.
` Q. And this is your response to his statement
`there, correct?
` A. Yes.
` Q. Now, I wanted to explore this a little
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`28
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 29
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`bit. The last sentence there, you say:
` To be clear, I consider the combination of
`azelastine and fluticasone in a formation suitable
`for nasal administration to be obvious for Claims 4
`and 42 through 44 for the same reasons as all the
`claims discussed herein.
` The "herein," are you referring to this
`declaration or is it both -- what do you mean with
`"herein"?
` A. This declaration.
` Q. Just this declaration? Does this
`declaration -- let me simplify this a little bit.
`I'll hand you the '620 patent first. That's
`Exhibit 1001, '620 patent. That's what this case is
`about, correct?
` A. Yes, I have certainly seen it.
` Q. If you flip back, you know where the
`claims are at the rear of the document. Claim 4 is
`in Column 11. It's page 13 as it's been stamped.
` A. Yes.
` Q. See Claim 4? The pharmaceutical
`formulation of Claim 1, wherein the said formulation
`
`www.DigitalEvidenceGroup.com
`
`Digital Evidence Group C'rt 2018
`
`202-232-0646
`
`29
`
`

`

`3/30/2018
`
`Argentum Pharmaceuticals LLC, v. Cipla, Ltd.
`
`Robert P. Schleimer
`
`Page 30
`has a particle size of less than 10 micrometers,
`correct?
` A. Yes.
` Q. Now, you just said that you have not
`been -- you don't have any experience or expertise
`in selecting particle size, correct?
` A. Well, as I said, I'm aware of issues that
`particle size influences. These issues vary
`depending on the context, for instance, with inhaled
`drugs versus

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket